Αρχική World News Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not Improve... World News Adding One Year of Palbociclib to Adjuvant Endocrine Treatment Does Not Improve OS or iDFS in High-Risk HR-positive, HER2-negative Primary Breast Cancer Από Ogkologos - 8 Απριλίου, 2025 991 0 Facebook Twitter Google+ Pinterest WhatsApp Final survival results from the PENELOPE-B study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Surprise! Financial Assistance To Help With Your Medical Bills May Be... 20 Δεκεμβρίου, 2023 President’s Cancer Panel Report: Closing Gaps in Cancer Screening for All... 3 Φεβρουαρίου, 2022 TG4001 Therapeutic Vaccination Plus Avelumab-Mediated PD-L1 Blockade Improves Tumour Microenvironment in... 12 Δεκεμβρίου, 2020 In the Name of Pinkness 8 Οκτωβρίου, 2020 Φόρτωση περισσοτέρων HOT NEWS Molecular Analysis for Precision Oncology Congress 2022, 14-16 October 2022, Amsterdam,... 癌症治疗期间如何保证日常活动的安全和独立执行 DNA from Ancient Viruses Helps Many Cancers Grow The digital shift: How are remote GP appointments affecting cancer patients?